Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C63H85N8O17.C2H3O2 |
Molecular Weight | 1285.4364 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC([O-])=O.[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@H](NC(=O)[C@]3([H])[C@@H](O)[C@@H](C)CN3C(=O)[C@@]([H])(NC(=O)C(NC2=O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@@H](C)O)OCC[N+](C)(C)C)NC(=O)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=C(OCCCCC)C=C7)[C@@H](C)O
InChI
InChIKey=MXMWJAPNUIKPGF-MLAUIKIVSA-N
InChI=1S/C63H84N8O17.C2H4O2/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81;1-2(3)4/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84);1H3,(H,3,4)/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51?,52-,53-,54-,55-,61+;/m0./s1
Molecular Formula | C2H3O2 |
Molecular Weight | 59.044 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C63H85N8O17 |
Molecular Weight | 1226.3924 |
Charge | 1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 14 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Biafungin (formerly SP 3025 or CD101), a highly stable echinocandin and an antifungal drug that was studied against panels of Candida and Aspergillus clinical isolates. Biafungin was involved in phase II clinical trials in the treatment of acute moderate to severe vulvovaginal candidiasis. Seachaid Pharmaceuticals invented this drug. Then Cidara Therapeutics acquired a worldwide exclusive license to develop and commercialize the drug.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02733432
CD101 (Biafungin) Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2. CD101 external gel (1%) applied topically twice daily over 72 hours as needed
Route of Administration:
Vaginal
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:16:31 GMT 2023
by
admin
on
Sat Dec 16 11:16:31 GMT 2023
|
Record UNII |
W1U1TMN677
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10432
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
PRIMARY | |||
|
CD-181
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
PRIMARY | |||
|
C152206
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
PRIMARY | |||
|
92135634
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
PRIMARY | |||
|
W1U1TMN677
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
PRIMARY | |||
|
1631754-41-0
Created by
admin on Sat Dec 16 11:16:31 GMT 2023 , Edited by admin on Sat Dec 16 11:16:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |